Pantoprazole Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
Therapeutic Class
Proton Pump Inhibitor (PPI)
Subclass
Benzimidazole Derivative
Speciality
Gastroenterology
Schedule (India)
Schedule H
Routes
Oral, Intravenous (IV)
Formulations
- Tablets (Enteric-coated): 20 mg, 40 mg
- Tablets (Gastro-resistant): 20 mg, 40 mg
- Injection (Lyophilised powder for reconstitution): 40 mg/vial
- Oral suspension: NOT AVAILABLE in India as monotherapy
Adult indications
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Gastroesophageal Reflux Disease (GERD)
| Parameter | Dose |
|---|---|
|
Starting dose
|
40 mg orally once daily (30–60 minutes before breakfast) |
|
Titration
|
Not typically required; if inadequate response after 4 weeks, evaluate for complications or alternative diagnosis |
|
Usual maintenance dose
|
20–40 mg once daily |
|
Maximum dose
|
40 mg twice daily (specialist discretion for refractory cases) |
Duration:
- Symptomatic GERD: 4 weeks initially; reassess
- Erosive GERD: 4–8 weeks
- Maintenance therapy: Consider step-down to 20 mg or on-demand use after healing
Clinical Notes:
- Administer before meals for optimal efficacy (requires acidic environment for activation)
- Reassess diagnosis if no response after 8 weeks of adequate therapy
- Consider endoscopy in non-responders or those with alarm features
2. Peptic Ulcer Disease (Gastric and Duodenal Ulcers)
Duodenal Ulcer:
| Parameter | Dose |
|---|---|
|
Starting dose
|
40 mg orally once daily |
|
Titration
|
Not applicable |
|
Usual maintenance dose
|
40 mg once daily |
|
Maximum dose
|
40 mg once daily |
Duration: 4 weeks (may extend to 8 weeks if not healed)
Gastric Ulcer:
| Parameter | Dose |
|---|---|
|
Starting dose
|
40 mg orally once daily |
|
Titration
|
Not applicable |
|
Usual maintenance dose
|
40 mg once daily |
|
Maximum dose
|
40 mg once daily |
Duration: 4–8 weeks
Clinical Notes:
- Rule out malignancy in gastric ulcers (biopsy recommended)
- Repeat endoscopy to confirm healing in gastric ulcers
3. Helicobacter pylori Eradication (as part of combination therapy)
| Parameter | Dose |
|---|---|
|
Starting dose
|
40 mg orally twice daily |
|
Titration
|
Not applicable |
|
Usual maintenance dose
|
40 mg twice daily |
|
Maximum dose
|
40 mg twice daily |
Standard Triple Therapy Regimen (14 days):
- Pantoprazole 40 mg twice daily + Amoxicillin 1 g twice daily + Clarithromycin 500 mg twice daily
Alternative (Bismuth Quadruple Therapy — 14 days):
- Pantoprazole 40 mg twice daily + Bismuth subsalicylate + Metronidazole + Tetracycline
Clinical Notes:
- 14-day regimens preferred over 7-day for higher eradication rates
- Consider local clarithromycin resistance patterns
- Confirm eradication with urea breath test or stool antigen (≥4 weeks after completing therapy and ≥2 weeks after stopping PPI)
4. Erosive Esophagitis
| Parameter | Dose |
|---|---|
|
Starting dose
|
40 mg orally once daily |
|
Titration
|
Not applicable |
|
Usual maintenance dose
|
40 mg once daily (healing); 20–40 mg once daily (maintenance) |
|
Maximum dose
|
40 mg twice daily (severe cases) |
Duration:
- Healing: 8 weeks
- Maintenance: Long-term in patients with high relapse risk (severe esophagitis, Barrett's oesophagus)
5. Zollinger-Ellison Syndrome and Pathological Hypersecretory Conditions
| Parameter | Dose |
|---|---|
|
Starting dose
|
40 mg orally twice daily |
|
Titration
|
Increase based on gastric acid output measurements; titrate to maintain basal acid output <10 mEq/hour |
|
Usual maintenance dose
|
80–160 mg/day in 1–2 divided doses |
|
Maximum dose
|
240 mg/day (in divided doses; specialist supervision required) |
Clinical Notes:
- Individualise dose based on acid output measurements
- May require long-term continuous therapy
- Monitor serum gastrin levels periodically
6. Stress Ulcer Prophylaxis in Critically Ill Patients (Intravenous — Hospital/ICU Setting Only)
| Parameter | Dose |
|---|---|
|
Starting dose
|
40 mg IV once daily |
|
Titration
|
Not applicable |
|
Usual maintenance dose
|
40 mg IV once daily |
|
Maximum dose
|
40 mg IV twice daily (bleeding prophylaxis in very high-risk patients) |
Indications for Stress Ulcer Prophylaxis:
- Mechanical ventilation >48 hours
- Coagulopathy (platelets <50,000 or INR >1.5)
- History of GI bleeding within past year
- Traumatic brain injury, spinal cord injury, burns >35% BSA
- Two or more minor risk factors (sepsis, ICU stay >1 week, occult GI bleed, high-dose corticosteroids)
Administration:
- Reconstitute with 10 mL normal saline or 5% dextrose
- Administer as IV bolus over 2–15 minutes OR as infusion over 15–30 minutes
- Transition to oral therapy as soon as enteral feeding established
Clinical Notes:
- Discontinue prophylaxis once patient is transferred out of ICU and tolerating enteral nutrition
- Avoid routine use outside approved indications (de-escalation protocols important)
Secondary Indications – Adults (Off-label)
| Indication | Dose | Duration | Supervision | Evidence Basis |
|---|---|---|---|---|
|
NSAID-induced Ulcer Prophylaxis (OFF-LABEL)
|
20–40 mg orally once daily | As long as NSAID therapy continues | Not required | API Textbook; AIIMS protocols; Indian rheumatology practice |
|
Functional Dyspepsia (Non-ulcer Dyspepsia) (OFF-LABEL)
|
20–40 mg orally once daily | Trial for 4–8 weeks; discontinue if no benefit | Not required | Limited efficacy; consider empirical trial; Indian GI practice |
|
Prevention of Aspiration Pneumonitis (Pre-operative) (OFF-LABEL)
|
40 mg orally the night before and morning of surgery | Single pre-operative use | Anaesthesia supervision | Anaesthesia protocols; reduces gastric acidity and volume |
|
Laryngopharyngeal Reflux (LPR) (OFF-LABEL)
|
40 mg orally twice daily | 8–12 weeks; reassess | ENT/GI specialist recommended | Limited evidence; trial may be warranted in suspected LPR |
Paediatric indications
PAEDIATRIC DOSING (Specialist Only)
⚠️ Not recommended in children below 5 years of age except under specialist supervision. Limited paediatric data available.
Primary Indications: GERD, Erosive Esophagitis
Oral Dosing (Children ≥5 years):
| Weight | Dose | Frequency | Duration |
|---|---|---|---|
|
15–40 kg
|
20 mg once daily | Once daily (before breakfast) | 8 weeks |
|
>40 kg
|
40 mg once daily | Once daily (before breakfast) | 8 weeks |
| Parameter | Dose |
|---|---|
|
Starting dose
|
Weight-based as above |
|
Titration
|
Not typically required |
|
Usual maintenance dose
|
20–40 mg once daily based on weight |
|
Maximum dose
|
40 mg once daily |
Intravenous Dosing (Hospital Setting — Limited Data):
- 0.8–1.6 mg/kg/day (maximum 40 mg/day)
- Specialist supervision required
Safety Monitoring:
- Monitor for symptoms of hypomagnesaemia with prolonged use
- Assess nutritional status (vitamin B12, calcium, magnesium) if therapy >8 weeks
- Evaluate for continued need periodically
Clinical Notes:
- Tablets should be swallowed whole; do not crush or chew (enteric-coated)
- If child cannot swallow tablets, consider omeprazole suspension or granules (better paediatric formulation availability)
Secondary Indications – Paediatrics (Off-label)
| Indication | Age | Dose | Duration | Supervision | Evidence Basis |
|---|---|---|---|---|---|
|
Stress Ulcer Prophylaxis in PICU (OFF-LABEL)
|
≥1 year | 0.5–1 mg/kg IV once daily (maximum 40 mg) | Duration of ICU risk factors | Specialist only (PICU) | Extrapolated from adult data; IAP protocols |
|
Zollinger-Ellison Syndrome (OFF-LABEL)
|
≥5 years | Individualised dosing based on acid output; starting 0.5–1 mg/kg twice daily | Long-term | Specialist only (Paediatric GI) | Case reports; extrapolated from adult data |
Age Restrictions:
- Not recommended below 5 years of age for routine use
- Use in children 1–5 years only under paediatric gastroenterology supervision
- Not recommended below 1 year of age
Renal Adjustments
No dose adjustment required in renal impairment (any severity).
| Renal Function | Recommendation |
|---|---|
|
Mild to Severe Impairment
|
No dose adjustment required |
|
Haemodialysis
|
No supplemental dose required; not significantly dialysed |
|
Peritoneal Dialysis
|
No dose adjustment required |
Note: Pantoprazole is primarily hepatically metabolised; renal excretion of unchanged drug is minimal.
Hepatic adjustment
Contraindications
- Known hypersensitivity to pantoprazole, substituted benzimidazoles, or any excipients
- Co-administration with rilpivirine (reduced rilpivirine absorption leading to virological failure and resistance)
- Co-administration with atazanavir (substantially reduced atazanavir absorption)
Cautions
- Long-term use (>8–12 weeks): Risk of vitamin B12 deficiency, hypomagnesaemia, increased fracture risk (hip, wrist, spine), Clostridioides difficile-associated diarrhoea
- Gastric malignancy: Rule out before initiating therapy; PPIs may mask symptoms of gastric cancer — investigate non-responders or those with alarm features (weight loss, dysphagia, GI bleeding, anaemia)
- Concurrent diuretics or digoxin: Monitor electrolytes (particularly magnesium and potassium)
- Chronic kidney disease: Although no dose adjustment needed, be aware of potential acute interstitial nephritis and chronic kidney disease progression with long-term PPI use
- Osteoporosis risk factors: Use lowest effective dose for shortest duration; ensure adequate calcium and vitamin D intake
- Lupus erythematosus: Rare reports of subacute cutaneous lupus erythematosus (SCLE) and systemic lupus exacerbation
- Fundic gland polyps: Increased risk with long-term use (>1 year); usually benign and reversible
Pregnancy
| Parameter | Information |
|---|---|
|
Overall Safety
|
Limited human data; animal studies show no teratogenicity; generally considered acceptable when indicated |
|
Risk
|
No confirmed teratogenic risk in humans; considered safer than untreated severe GERD |
|
Preferred Alternatives
|
Omeprazole (most human pregnancy data available among PPIs); antacids or H2 blockers for mild symptoms |
|
When Use May Be Justified
|
Moderate to severe GERD unresponsive to lifestyle modifications and antacids; erosive esophagitis; use at lowest effective dose for shortest duration |
|
Monitoring
|
Maternal symptom control; no specific fetal monitoring required |
Lactation
| Parameter | Information |
|---|---|
|
Compatibility
|
Likely compatible; very low levels expected in breast milk based on pharmacokinetic properties |
|
Expected Drug Level in Milk
|
Very low (pantoprazole is highly protein-bound and acid-labile) |
|
Preferred Alternatives
|
Omeprazole (more breastfeeding data available); famotidine (H2 blocker) |
|
Infant Monitoring
|
Monitor for GI disturbances (diarrhoea, constipation), feeding difficulties, weight gain (rare concerns) |
|
Recommendation
|
Generally acceptable for short-term use during breastfeeding |
Elderly
| Parameter | Recommendation |
|---|---|
|
Starting dose
|
20–40 mg once daily (same as adults; consider starting at 20 mg) |
|
Titration
|
Not typically required; use lowest effective dose |
|
Maximum recommended
|
40 mg once daily for most indications; avoid high doses unless clearly indicated |
|
Increased Risks
|
Increased fracture risk (hip, spine, wrist); hypomagnesaemia (especially with concurrent diuretics); vitamin B12 deficiency with long-term use; Clostridioides difficile infection; pneumonia (community-acquired) |
|
Additional Precautions
|
Review indication periodically; de-escalate or discontinue when possible; ensure adequate calcium, vitamin D, and B12 intake; monitor magnesium levels if on long-term therapy or diuretics |
Major drug interactions
| Interacting Drug | Mechanism | Effect | Management |
|---|---|---|---|
|
Rilpivirine
|
Reduced gastric acidity decreases rilpivirine absorption | Significant reduction in rilpivirine levels; risk of HIV treatment failure and resistance |
Contraindicated — avoid combination
|
|
Atazanavir
|
Reduced gastric acidity decreases atazanavir absorption | Significantly reduced atazanavir levels; risk of HIV treatment failure |
Contraindicated — avoid combination; if unavoidable, use atazanavir/ritonavir 400/100 mg with food, PPI ≤20 mg, and administer simultaneously
|
|
Methotrexate (high-dose)
|
Possible inhibition of renal tubular secretion of methotrexate | Increased methotrexate levels and toxicity risk | Consider temporary PPI discontinuation during high-dose methotrexate therapy; monitor methotrexate levels |
|
Clopidogrel
|
CYP2C19 inhibition (minimal with pantoprazole) | Potential reduction in active clopidogrel metabolite (less significant than with omeprazole/esomeprazole) | Pantoprazole preferred PPI if PPI required with clopidogrel; cardiology input if recent ACS/PCI |
Moderate drug interactions
| Interacting Drug | Effect | Management |
|---|---|---|
|
Warfarin
|
Variable reports of increased INR | Monitor INR when initiating or discontinuing pantoprazole; adjust warfarin dose as needed |
|
Digoxin
|
Increased digoxin absorption due to elevated gastric pH | Monitor digoxin levels, especially in elderly or those with renal impairment; risk higher if hypomagnesaemia present |
|
Iron supplements (ferrous salts)
|
Reduced iron absorption due to elevated gastric pH | Take iron supplement with food or vitamin C; consider parenteral iron if deficiency persists |
|
Ketoconazole, Itraconazole, Posaconazole
|
Reduced antifungal absorption (requires acidic environment) | Separate dosing; use antifungals that do not require acidic pH (fluconazole, voriconazole); or administer with acidic beverage |
|
Vitamin B12
|
Reduced absorption with long-term PPI use | Monitor B12 levels annually in long-term users; supplement if deficient |
|
Mycophenolate mofetil
|
Reduced absorption of mycophenolic acid (enteric-coated formulation) | Monitor mycophenolate levels and clinical efficacy; consider mycophenolate sodium if clinically appropriate |
|
Bisphosphonates (oral)
|
No direct interaction but additive bone risk | Ensure adequate calcium and vitamin D; monitor bone health in long-term concurrent use |
|
Tacrolimus
|
Possible increased tacrolimus levels | Monitor tacrolimus trough levels when initiating or discontinuing PPI |
Common Adverse effects
- Headache
- Diarrhoea
- Nausea
- Abdominal pain, flatulence
- Dizziness
- Arthralgia
- Constipation
- Dry mouth
- Rash (mild)
Serious Adverse effects
| Adverse Effect | Clinical Action |
|---|---|
|
Clostridioides difficile-associated diarrhoea (CDAD)
|
Discontinue PPI; test for C. difficile toxin; treat as per guidelines; consider alternative acid suppression if essential |
|
Hypomagnesaemia (may cause tetany, arrhythmias, seizures)
|
Check magnesium levels; discontinue PPI; supplement magnesium; may recur on rechallenge |
|
Acute Interstitial Nephritis
|
Discontinue immediately; nephrology referral; usually reversible but may progress to chronic kidney disease |
|
Vitamin B12 Deficiency (with long-term use)
|
Monitor annually in long-term users; supplement if deficient |
|
Bone Fractures (hip, spine, wrist — with long-term high-dose use)
|
Use lowest effective dose; ensure calcium and vitamin D adequacy; bone density monitoring in high-risk patients |
|
Subacute Cutaneous Lupus Erythematosus (SCLE) (rare)
|
Discontinue PPI; dermatology referral; rash usually resolves after discontinuation |
|
Fundic Gland Polyps (benign; with long-term use)
|
Usually benign; endoscopic surveillance as per GI practice; often regress after PPI discontinuation |
|
Anaphylaxis / Angioedema (rare)
|
Discontinue permanently; emergency management |
|
Severe Skin Reactions (SJS/TEN) (very rare)
|
Discontinue immediately; hospitalisation; dermatology consultation |
Monitoring requirements
| Timing | Parameters |
|---|---|
|
Baseline
|
Evaluate for alarm symptoms (dysphagia, weight loss, GI bleeding, persistent vomiting) — endoscopy if indicated; serum magnesium if on diuretics or long-term PPI therapy |
|
Short-term use (<8 weeks)
|
No routine monitoring required |
|
Long-term use (>8–12 weeks)
|
Serum magnesium (especially if on diuretics, digoxin); vitamin B12 annually; reassess indication for continued PPI use |
|
If on warfarin
|
INR monitoring when initiating or stopping PPI |
|
If on digoxin
|
Digoxin levels, especially if hypomagnesaemia suspected |
|
Zollinger-Ellison Syndrome
|
Gastric acid output measurements; serum gastrin levels periodically |
Brands in India
Tablets (20 mg, 40 mg):
- Pantocid™ (Sun Pharma)
- Pan™ (Alkem)
- Pantop™ (Aristo)
- P-40™, Pantozee™
- Nupenta™ (Zydus)
- Pansec™
- Protium™
Injection (40 mg):
- Pantocid IV™ (Sun Pharma)
- Pan IV™ (Alkem)
- Pantop IV™ (Aristo)
Fixed-Dose Combinations (Examples):
- Pantoprazole + Domperidone (e.g., Pantocid-D, Pan-D) — commonly used but monitor for QT prolongation with domperidone
- Pantoprazole + Itopride (e.g., Pantocar-IT)
- Pantoprazole + Levosulpiride
⚠️ Note on Domperidone FDCs: Monitor for QT prolongation risk, especially in elderly, cardiac patients, or those on other QT-prolonging drugs. Domperidone dose should not exceed 30 mg/day.
Price range (INR)
| Formulation | Price Range | Notes |
|---|---|---|
| 20 mg tablet | ₹1.50–₹5.00 per tablet | NLEM listed |
| 40 mg tablet | ₹2.50–₹10.00 per tablet | NLEM listed |
| 40 mg injection | ₹35–₹100 per vial | — |
| FDCs (Pantoprazole + Domperidone) | ₹4–₹12 per tablet | — |
Regulatory: Listed under NLEM 2022 (40 mg tablet); NPPA price controlled for scheduled strengths
Clinical pearls
- Preferred PPI with clopidogrel — Pantoprazole has minimal CYP2C19 inhibition compared to omeprazole and esomeprazole; preferred choice when PPI is required in patients on dual antiplatelet therapy post-ACS/PCI
- Timing of administration is critical — Administer 30–60 minutes before the first meal of the day; PPIs require active acid secretion (stimulated by food) for optimal activation in parietal cells
- De-escalation and deprescribing — Review indication periodically; many patients continue PPIs beyond appropriate duration; step-down to H2 blocker or on-demand PPI after healing; avoid indefinite therapy without clear indication
- Rule out malignancy — Always consider endoscopy in patients with alarm features (dysphagia, weight loss, GI bleeding, persistent vomiting, anaemia) or non-responders to adequate PPI therapy; PPIs can mask symptoms of gastric cancer
- Monitor long-term users — Check magnesium (especially if on diuretics), vitamin B12 annually, and assess bone health in those with osteoporosis risk factors; ensure adequate calcium and vitamin D intake
- FDC caution — Pantoprazole + Domperidone combinations are widely prescribed in India; be aware of domperidone-associated QT prolongation risk, especially in elderly and cardiac patients
Version
RxIndia v1.0 — 28 Apr 2025
Reference
- CDSCO Product Information
- Indian Pharmacopoeia (IP)
- National Formulary of India (NFI)
- National List of Essential Medicines (NLEM) 2022
- API Textbook of Medicine
- AIIMS Drug Formulary and Treatment Protocols
- ICMR Guidelines
- Harrison's Principles of Internal Medicine
- Goodman & Gilman's The Pharmacological Basis of Therapeutics
- IAP Guidelines (paediatric dosing support)
- WHO Essential Medicines List (paediatric support)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.